Biomarker analysis from a phase I/I1b study of regorafenib and nivolumab (rego/nivo) in microsatellite stable (MSS) colorectal cancer (CRC).
Yu J, Kim Y, Mehta R, Miao R, Strosberg J, Imanirad I, Kim D, Kim R. Biomarker analysis from a phase I/I1b study of regorafenib and nivolumab (rego/nivo) in microsatellite stable (MSS) colorectal cancer (CRC). Journal Of Clinical Oncology 2023, 41: 188-188. DOI: 10.1200/jco.2023.41.4_suppl.188.Peer-Reviewed Original ResearchPathway enrichment analysisReceptor signaling pathwayEnrichment analysisProgressive diseaseB cell activationGene OntologyCell-substrate junction assemblySignaling pathwayGO pathway enrichment analysisPositive regulation of B cell activationDownregulated pathwaysKyoto Encyclopedia of GenesSerine-type endopeptidase activityPredictive biomarkersMSS-CRCKEGG pathway enrichment analysisRegulation of B cell activationECM-receptor interactionTumor samplesEncyclopedia of GenesColorectal cancerGenomes (KEGGExtracellular matrixPre-treatment tumor samplesGene set enrichment analysis